HSS, pSivida enter orthopedic evaluation agreement

Download PDF Copy

Aug 17 2011

Drug delivery company pSivida Corp. (NASDAQ: PSDV) (ASX: PVA) today announced it has entered into an evaluation agreement with Hospital for Special Surgery (HSS), a world leader in orthopedics, rheumatology and rehabilitation, to investigate pSivida's drug delivery technologies in orthopedics.

This agreement follows pSivida's announcement in June that it has renegotiated its collaboration agreement with Pfizer to focus solely on developing a bioerodible sustained release implant for glaucoma and ocular hypertension.

"We believe this orthopedic evaluation agreement is important for pSivida as our drug delivery technology, originally developed for ophthalmology, is being investigated in broader areas of medicine," said Dr Paul Ashton, President and CEO of pSivida. "We are excited to be working with Hospital for Special Surgery because of their long history of innovation and research in orthopaedic surgery."

Source:

pSivida Corp.

Posted in: Device / Technology News | Medical Procedure News | Medical Condition News

Comments (0)

Download PDF Copy

Suggested Reading

COPD care pathways improve hospital outcomes and standardize treatment

Many people unaware that knee and groin pain could signal hip problems

Watch: Patient numbers at NIH hospital tumble after Trump cuts

New clinical trial to test sensory-enabled neural prostheses for upper limb amputees

Study validates deep learning model for predicting future lung cancer risk in Black population

Certain dietary fats found to trigger hard-to-treat asthma in children

Portable ultrasound improves diagnosis and patient outcomes

NYU Langone stroke team delivers lifesaving care with record speed

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.